14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $0.0060 $169.56 Friday, 27th Jan 2023 GBT stock ended at $68.49. During the day the stock fluctuated 0% from a day low at $68.49 to a day high of $68.49.
90 days $113.65 $133.77
52 weeks $171.20 $133.77

Historical GLOBAL BLOOD THERAPEUTICS prices

Date Open High Low Close Volume
Oct 25, 2016 $20.75 $21.65 $19.25 $19.75 2 579 200
Oct 24, 2016 $18.95 $18.95 $17.70 $17.75 326 900
Oct 21, 2016 $18.50 $19.10 $18.47 $18.85 332 900
Oct 20, 2016 $18.00 $18.88 $17.95 $18.70 276 400
Oct 19, 2016 $18.30 $18.45 $17.70 $18.05 293 400
Oct 18, 2016 $17.65 $18.25 $17.30 $18.15 185 200
Oct 17, 2016 $17.45 $17.70 $16.90 $17.25 293 700
Oct 14, 2016 $18.10 $18.11 $16.81 $17.50 397 200
Oct 13, 2016 $17.45 $18.25 $17.11 $18.20 320 800
Oct 12, 2016 $18.15 $18.65 $17.35 $17.60 355 200
Oct 11, 2016 $18.50 $18.65 $17.55 $18.25 435 000
Oct 10, 2016 $18.90 $19.10 $18.35 $18.60 341 100
Oct 07, 2016 $18.70 $19.20 $17.85 $18.50 547 900
Oct 06, 2016 $19.30 $19.85 $17.55 $18.80 1 158 500
Oct 05, 2016 $22.85 $23.25 $18.80 $19.60 1 884 900
Oct 04, 2016 $22.40 $23.15 $21.80 $22.50 344 600
Oct 03, 2016 $23.25 $23.80 $21.35 $22.30 415 600
Sep 30, 2016 $22.39 $23.24 $21.65 $23.05 1 445 900
Sep 29, 2016 $21.77 $21.79 $20.25 $20.46 272 500
Sep 28, 2016 $22.17 $22.17 $21.16 $21.83 198 000
Sep 27, 2016 $21.93 $22.09 $21.12 $22.02 304 400
Sep 26, 2016 $22.53 $22.53 $21.81 $21.95 190 200
Sep 23, 2016 $23.36 $24.10 $22.64 $22.75 366 200
Sep 22, 2016 $23.71 $23.71 $22.63 $23.41 407 900
Sep 21, 2016 $22.92 $23.88 $22.83 $23.50 582 000
Click to get the best stock tips daily for free!

About GLOBAL BLOOD THERAPEUTICS

GLOBAL BLOOD THERAPEUTICS Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, ... GBT Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT